NeoGenomics quarterly revenue rises 11.4% to $209.3 million
NeoGenomics' revenue growth is holding steady. Results for the quarter ended September 30, 2026, from the earnings release filed with the SEC on Oct 28, 2026.
Snapshot
NeoGenomics' revenue growth is holding steady: revenue rose 11.4% to $209.3 million in the quarter ended September 30, 2026, from $187.8 million a year earlier, after 11.2% year over year growth the quarter before.
- Independent Research
Market Data
| Company | 1D % | Price |
|---|---|---|
| ($NEO) | ▼ −0.42% | 17.91 |
as of 16:00 ET · Realtime derived data
What We Know
Revenue for the quarter ended September 30, 2026 was $209.3 million, versus $187.8 million in the same quarter a year earlier, up 11.4%. That is its highest quarterly revenue of the last eight quarters.
Quarterly revenue by fiscal quarter end, oldest first: Dec 2024: $172.0 million; Mar 2025: $168.0 million; Jun 2025: $181.3 million; Sep 2025: $187.8 million; Dec 2025: $190.2 million; Mar 2026: $186.7 million; Jun 2026: $201.7 million; Sep 2026: $209.3 million.
Octans View
Year over year revenue change by quarter, computed from the filed figures: Dec 2025 up 10.6%; Mar 2026 up 11.1%; Jun 2026 up 11.2%; Sep 2026 up 11.4%. On those figures, NeoGenomics' revenue growth is holding steady. That read compares the latest two year over year growth rates and nothing else.
Bear Case · Room for Disagreement
This brief covers reported revenue and diluted earnings per share only. It does not cover guidance, margins, segment results, cash flow or the earnings call, and it makes no forecast. Revenue is the total on the release line we matched; a company's own adjusted measures can differ.
Method and source. Octans Research matched the revenue line in the earnings release (Exhibit 99.1) to the year ago quarter the company reported in its own XBRL financial data; the two must agree before anything is published. The quarterly history comes from the same XBRL data. The text is generated from those verified figures by a fixed template; no model wrote it.
Chart
Sources
- [1]SEC EDGAR — NeoGenomics earnings release for the quarter ended September 30, 2026 (Exhibit 99.1), filed Oct 28, 2026
- [2]SEC EDGAR — NeoGenomics XBRL financial data (company facts)
These are the sources this piece was drafted from. How we verify. Found an error? Tell us and we correct it in public.
$209.3M
More on $NEO
4 reports
NewMarket quarterly revenue rises 3.8% to $716.5 million
NewMarket's revenue growth is slowing. Results for the quarter ended September 30, 2026, from the earnings release filed with the SEC on Oct 28, 2026.
WEX quarterly revenue rises 12.8% to $780.1 million
WEX's revenue growth is slowing. Results for the quarter ended September 30, 2026, from the earnings release filed with the SEC on Oct 28, 2026.
Darling Ingredients quarterly revenue rises 14.5% to $1.79 billion
Darling Ingredients' revenue growth is slowing. Results for the quarter ended October 3, 2026, from the earnings release filed with the SEC on Oct 28, 2026.
Churchill Downs quarterly revenue rises 1.9% to $696.0 million
Churchill Downs' revenue growth has more than halved. Results for the quarter ended September 30, 2026, from the earnings release filed with the SEC on Oct 28, 2026.